Accuray Inc
ARAY
Detailliertes Diagramm anzeigen
1.220USD
-0.230-15.86%
Handelsschluss 11/06, 16:00（ET）Kurse um 15 Minuten verzögert
138.20MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-15.86%
5 Tage
-11.59%
1 Monat
-28.65%
6 Monate
-6.15%
Seit Jahresbeginn
-38.38%
1 Jahr
-39.90%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Accuray Inc
Währung: USD Aktualisiert: 2025-11-06Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ stabil. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Starker Kauf bewertet. Trotz einer sehr schwachen Marktentwicklung zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Accuray Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
2
Analysten
Starker Kauf
Aktuelles Rating
4.250
Kursziel
+193.10%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Accuray Inc Highlights
HöhepunkteRisiko
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-7.71)
institutional_increasing_position
institutional_increasing_position_desc%!(EXTRA string=81.62M, string=13.24%)
institutional_hold%!(EXTRA string=PRFDX)
institutional_hold_desc%!(EXTRA string=PRFDX, string=8.32K)
Accuray Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Accuray Inc Informationen
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
BörsenkürzelARAY
UnternehmenAccuray Inc
CEOMs. Suzanne C. Winter
Websitehttps://www.accuray.com/
Verwandte Finanzinstrumente
-1.89%
+0.33%
-0.29%
-0.14%
-0.73%
+0.15%
-1.08%
-0.38%
-0.39%
+0.14%
+1.76%
-1.14%
-1.23%
-0.90%
+0.57%
-0.48%
-1.37%
+0.49%
-0.09%
+1.81%Beliebte Symbole
